KR102099596B1 - 염증성 장애 치료용 조성물 및 방법 - Google Patents

염증성 장애 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR102099596B1
KR102099596B1 KR1020167014386A KR20167014386A KR102099596B1 KR 102099596 B1 KR102099596 B1 KR 102099596B1 KR 1020167014386 A KR1020167014386 A KR 1020167014386A KR 20167014386 A KR20167014386 A KR 20167014386A KR 102099596 B1 KR102099596 B1 KR 102099596B1
Authority
KR
South Korea
Prior art keywords
antibody
fractalcaine
seq
artificial sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167014386A
Other languages
English (en)
Korean (ko)
Other versions
KR20160066055A (ko
Inventor
미유키 니시무라
요시마사 사카모토
데쓰 가와노
도시오 이마이
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102099596(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20160066055A publication Critical patent/KR20160066055A/ko
Application granted granted Critical
Publication of KR102099596B1 publication Critical patent/KR102099596B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167014386A 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법 Active KR102099596B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30
US61/256,521 2009-10-30
PCT/JP2010/069653 WO2011052799A1 (en) 2009-10-30 2010-10-28 Compositions and methods for treating inflammatory disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127014048A Division KR101627605B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20160066055A KR20160066055A (ko) 2016-06-09
KR102099596B1 true KR102099596B1 (ko) 2020-04-10

Family

ID=43922220

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127014048A Active KR101627605B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법
KR1020167014386A Active KR102099596B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020127014048A Active KR101627605B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법

Country Status (33)

Country Link
US (1) US8932592B2 (enExample)
EP (1) EP2493930B1 (enExample)
JP (2) JP5631991B2 (enExample)
KR (2) KR101627605B1 (enExample)
CN (1) CN102597003B (enExample)
AR (2) AR078796A1 (enExample)
AU (1) AU2010312408B2 (enExample)
BR (1) BR112012010266A2 (enExample)
CA (1) CA2778895C (enExample)
CL (2) CL2012001143A1 (enExample)
CY (1) CY1121167T1 (enExample)
DK (1) DK2493930T3 (enExample)
ES (1) ES2698389T3 (enExample)
HR (1) HRP20181973T1 (enExample)
HU (1) HUE041952T2 (enExample)
IL (1) IL219470A (enExample)
JO (1) JO3437B1 (enExample)
LT (1) LT2493930T (enExample)
MX (1) MX2012005052A (enExample)
MY (1) MY158481A (enExample)
NZ (1) NZ599779A (enExample)
PE (1) PE20121645A1 (enExample)
PH (1) PH12012500828A1 (enExample)
PL (1) PL2493930T3 (enExample)
PT (1) PT2493930T (enExample)
RS (1) RS58142B1 (enExample)
RU (1) RU2569109C2 (enExample)
SI (1) SI2493930T1 (enExample)
SM (1) SMT201800637T1 (enExample)
TW (1) TWI414308B (enExample)
UA (1) UA105073C2 (enExample)
WO (1) WO2011052799A1 (enExample)
ZA (1) ZA201203002B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
US20220196674A1 (en) * 2019-04-17 2022-06-23 Abdolamir Landi Treatment of autoimmune liver disease
WO2020218232A1 (ja) 2019-04-23 2020-10-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチ治療のためのバイオマーカー
BR112022011280A2 (pt) * 2019-12-09 2022-09-06 Alexion Pharma Inc Anticorpo anti-cd5 para o tratamento da disfunção do espectro da neuromielite óptica
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
WO2022092183A1 (ja) 2020-10-30 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
WO2009036209A2 (en) * 2007-09-14 2009-03-19 Amgen Inc. Homogeneous antibody populations

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
CN1196733A (zh) 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
CA2240409C (en) 1996-01-24 2011-03-22 Schering Corporation Mammalian cx3c chemokine genes
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
AU730989B2 (en) 1996-05-07 2001-03-22 Millennium Pharmaceuticals, Inc. Neurotactin and uses therefor
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
CA2341361A1 (en) 1998-08-31 2000-03-09 Oregon Health Sciences University Prevention of cell migration initiation with cmv us28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
AU2002323570A1 (en) 2001-08-30 2003-03-10 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
EP1671648A4 (en) 2003-10-02 2009-07-08 Eisai R&D Man Co Ltd PREVENTION AND TREATMENT OF GVHD
EP1675862A1 (en) 2003-10-07 2006-07-05 AstraZeneca AB New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
JP4958555B2 (ja) * 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
ES2410886T3 (es) 2006-10-26 2013-07-03 Janssen Biotech, Inc. Métodos para la adaptación al ser humano de anticuerpos monoclonales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
US7390490B1 (en) 2001-03-19 2008-06-24 Eisai Co., Ltd. Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
WO2009036209A2 (en) * 2007-09-14 2009-03-19 Amgen Inc. Homogeneous antibody populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEBS Letters, 2004, 제561권, 페이지 105-110

Also Published As

Publication number Publication date
BR112012010266A2 (pt) 2016-12-06
IL219470A (en) 2017-10-31
HUE041952T2 (hu) 2019-06-28
TW201127401A (en) 2011-08-16
TWI414308B (zh) 2013-11-11
MX2012005052A (es) 2012-05-29
HRP20181973T1 (hr) 2019-01-25
JP2015027304A (ja) 2015-02-12
EP2493930A4 (en) 2013-12-04
EP2493930A1 (en) 2012-09-05
KR101627605B1 (ko) 2016-06-07
WO2011052799A1 (en) 2011-05-05
CN102597003A (zh) 2012-07-18
KR20120104560A (ko) 2012-09-21
SI2493930T1 (sl) 2018-12-31
RU2569109C2 (ru) 2015-11-20
JO3437B1 (ar) 2019-10-20
MY158481A (en) 2016-10-14
PL2493930T3 (pl) 2019-03-29
ES2698389T3 (es) 2019-02-04
AR078796A1 (es) 2011-12-07
EP2493930B1 (en) 2018-09-19
LT2493930T (lt) 2019-01-10
AU2010312408B2 (en) 2015-07-09
UA105073C2 (uk) 2014-04-10
RS58142B1 (sr) 2019-02-28
CA2778895A1 (en) 2011-05-05
CY1121167T1 (el) 2020-05-29
CN102597003B (zh) 2016-03-23
KR20160066055A (ko) 2016-06-09
PT2493930T (pt) 2018-11-29
IL219470A0 (en) 2012-06-28
SMT201800637T1 (it) 2019-01-11
US8932592B2 (en) 2015-01-13
CA2778895C (en) 2018-08-07
US20120213799A1 (en) 2012-08-23
JP5631991B2 (ja) 2014-11-26
NZ599779A (en) 2014-03-28
CL2015000114A1 (es) 2015-04-10
DK2493930T3 (en) 2018-12-17
CL2012001143A1 (es) 2012-10-05
PH12012500828A1 (en) 2013-01-07
PE20121645A1 (es) 2012-12-06
AR109533A2 (es) 2018-12-19
AU2010312408A1 (en) 2012-06-21
RU2012122203A (ru) 2013-12-10
ZA201203002B (en) 2013-06-26
JP2013509158A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
KR102099596B1 (ko) 염증성 장애 치료용 조성물 및 방법
US9150653B2 (en) CD127 binding proteins
CN101687035B (zh) 新化合物
CN101809035B (zh) 能结合胸腺基质淋巴细胞生成素的抗原结合蛋白
JP6236478B2 (ja) 血清アミロイドｐ成分に特異的な抗原結合タンパク質
EP2200699A1 (en) Antigen binding proteins
HK1174041A (en) Improved anti human fraktalkine antibodies and uses thereof
HK1174041B (en) Improved anti human fraktalkine antibodies and uses thereof
WO2011080050A2 (en) Binding molecules
EA040834B1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К IL-23p19 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, ЕГО ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ УКАЗАННОЕ АНТИТЕЛО

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160530

Application number text: 1020127014048

Filing date: 20120530

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160629

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190806

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200227

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200406

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200407

End annual number: 3

Start annual number: 1

PG1601 Publication of registration